WO2026040870A1 - Composé ciblant la phosphodiestérase de sous-type pde4b et son utilisation - Google Patents

Composé ciblant la phosphodiestérase de sous-type pde4b et son utilisation

Info

Publication number
WO2026040870A1
WO2026040870A1 PCT/CN2025/114187 CN2025114187W WO2026040870A1 WO 2026040870 A1 WO2026040870 A1 WO 2026040870A1 CN 2025114187 W CN2025114187 W CN 2025114187W WO 2026040870 A1 WO2026040870 A1 WO 2026040870A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
substituted
haloalkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2025/114187
Other languages
English (en)
Chinese (zh)
Inventor
贺耘
王淼
关良宇
周子岚
高振
熊义
车超
卢江
苏家冕
朱振东
万青
陈虹
杨建峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuwai Hospital of CAMS and PUMC
Shenzhen Bay Laboratory
Original Assignee
Fuwai Hospital of CAMS and PUMC
Shenzhen Bay Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuwai Hospital of CAMS and PUMC, Shenzhen Bay Laboratory filed Critical Fuwai Hospital of CAMS and PUMC
Publication of WO2026040870A1 publication Critical patent/WO2026040870A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé ciblant la phosphodiestérase subtype PDE4B ou un sel pharmaceutiquement acceptable de celui-ci, et son procédé de préparation. La structure du composé est représentée par la formule I. L'invention concerne également une composition pharmaceutique comprenant le composé ou un sel pharmaceutiquement acceptable de celui-ci, et son utilisation dans le traitement de maladies médiées par PDE4B de sous-type phosphodiestérase.
PCT/CN2025/114187 2024-08-23 2025-08-12 Composé ciblant la phosphodiestérase de sous-type pde4b et son utilisation Pending WO2026040870A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202411173731.6 2024-08-23
CN202411173731 2024-08-23

Publications (1)

Publication Number Publication Date
WO2026040870A1 true WO2026040870A1 (fr) 2026-02-26

Family

ID=98864468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2025/114187 Pending WO2026040870A1 (fr) 2024-08-23 2025-08-12 Composé ciblant la phosphodiestérase de sous-type pde4b et son utilisation

Country Status (1)

Country Link
WO (1) WO2026040870A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102883723A (zh) * 2009-12-31 2013-01-16 大塚制药株式会社 治疗化合物及相关的使用方法
WO2014170020A1 (fr) * 2013-04-16 2014-10-23 Grünenthal GmbH Composés de pyrimidine condensés substitués

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102883723A (zh) * 2009-12-31 2013-01-16 大塚制药株式会社 治疗化合物及相关的使用方法
WO2014170020A1 (fr) * 2013-04-16 2014-10-23 Grünenthal GmbH Composés de pyrimidine condensés substitués

Similar Documents

Publication Publication Date Title
TWI828008B (zh) Glp-1r調節化合物
JP7208142B2 (ja) Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体
CN101098872B (zh) 可用作蛋白激酶抑制剂的吡咯并吡嗪和吡唑并吡嗪
US20230219946A1 (en) Pyrimidin-4(3h)-one heterocyclic compound, preparation method thereof, and pharmaceutical use thereof
JP2021500330A (ja) Ｐａｄ阻害剤としてのイミダゾ−ピリジン化合物
WO2015026683A1 (fr) Composés inhibant l'activité enzymatique de la kinase à répétitions riches en leucine
CN101528729A (zh) 作为gsk-3抑制剂的嘧啶酮化合物
BR112015009168B1 (pt) Composto de fórmula estrutural xi ou um sal do mesmo, uso de um composto e composição farmacêutica
KR20190045242A (ko) 메닌-mll 상호작용의 스피로 바이사이클릭 억제제
CN114829363B (zh) 腺苷受体拮抗剂化合物
WO2012022121A1 (fr) Composé cyclique fusionné utilisé comme antagoniste des récepteurs des minéralocorticoïdes
JP2023539275A (ja) 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体
JP2023522863A (ja) Ｅｇｆｒ阻害剤としての三環式化合物
TW202043232A (zh) Pde9抑制劑及其用途
CN116262750A (zh) 一种芳杂环类化合物及其制备方法和用途
JP2021529819A (ja) Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体
JP7406008B2 (ja) Ｃｄｋ９阻害剤としての多環式アミド系誘導体、その調製方法及び用途
WO2026040870A1 (fr) Composé ciblant la phosphodiestérase de sous-type pde4b et son utilisation
WO2022155111A1 (fr) Dérivés d'indole en tant qu'inhibiteurs de kinase
RU2839367C1 (ru) Гетероциклическое соединение пиримидин-4(3h)-она, способ его получения и его фармацевтическое применение
Bhalay Preparation of tyrosine amide derivatives as Rho-​ kinase inhibitors
AU2006228142A1 (en) Imidazopyridine derivatives useful as iNOS inhibitors
WO2025196155A1 (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
HK40097385A (zh) 腺苷受体拮抗剂化合物及其应用
CN114206866A (zh) 前列腺素e2受体4拮抗剂及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25856040

Country of ref document: EP

Kind code of ref document: A1